Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings

In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet